Bloom 2003.

Methods	Study Design: Parallel RCT Randomisation: Random stated, method not described. Concealment of Allocation: not stated. Double Blinding: Yes. Withdrawals / dropouts: Described. Adverse events: not stated. Statistical analysis: not stated. Jadad Score: 3
Participants	Study site: No eligible: No randomised: 574 No completed: 288 Sex: Males ‐not stated; Females ‐not stated Age: not stated. Diagnostic criteria for asthma: not stated. Inclusion criteria: Requiring moderate dose maintenance ICS (FP 220bid equivalent) to maintain asthma control. Exclusion criteria: not stated. Baseline severity of asthma: FEV1 mean 78% predicted
Interventions	Run in phase: not stated 1: Fluticasone/Salmeterol 100/50mcg combination bid (200/100mcg/day) 2: Fluticasone 250mcg bid (500mcg/day) Delivery device: DPI, single device Duration of treatment: 24 weeks Other:
Outcomes	All measured as change from baseline: Withdrawal due to worsening asthma, FEV1(L), morning PEF (L/min), rescue medication use (puffs/day), % symptom free days
Notes	Abstract only. Comparison 1: Constant dose ICS
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Described as randomised; no other information available
Allocation concealment?	Unclear risk	Information not available
Blinding? All outcomes	Unclear risk	Information not available